Hydroxamates as therapeutic agents

Details Hydroxamates as therapeutic agents Hydroxamates as therapeutic agents

2007-08-06

2008-09-02

Kumar, Shailendra (Department: 1621)

Organic compounds -- part of the class 532-570 series

Organic compounds

Hydroxamic acids, chalcogen analogs or salts thereof

C560S312000, C514S507000, C514S575000

Reexamination Certificate

active

07420089

ABSTRACT:
The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.

REFERENCES:
patent: 4999378 (1991-03-01), Fujii et al.
patent: 5254731 (1993-10-01), Zimmer et al.
patent: 5972978 (1999-10-01), Andersen et al.
patent: 6211197 (2001-04-01), Belley et al.
patent: 6960685 (2005-11-01), Watkins et al.
patent: 7276612 (2007-10-01), Verner et al.
patent: 2004/0053908 (2004-03-01), Funahashi et al.
patent: 2004/0077726 (2004-04-01), Watkins et al.
patent: 2007/0293540 (2007-12-01), Verner et al.
patent: 0084236 (1983-07-01), None
patent: 0394440 (1990-10-01), None
patent: WO-1995-05358 (1995-02-01), None
patent: WO-2000-20371 (2000-04-01), None
patent: WO-2001-14331 (2001-03-01), None
patent: WO-2001-38322 (2001-05-01), None
patent: WO-2002-26703 (2002-04-01), None
patent: WO-2002-30879 (2002-04-01), None
patent: WO-2003-013493 (2003-02-01), None
patent: WO-2003-070691 (2003-08-01), None
patent: WO-2004-013130 (2004-02-01), None
Carter et al., Chemotherapy of Cancer, second edition, John Wiley & Sons, N.Y., N.Y., 1981, pp. 362-365.
U.S. Appl. No. 11/940,260, filed Nov. 14, 2007, Verner et al.
U.S. Appl. No. 11/940,273, filed Nov. 14, 2007, Verner et al.
Brzozowski, Z. et al., “Derivatives of 2-Mercapobenzenesulphonamide XI. Synthesis and Some Pharmacological Properties of 2-{2—[2-(3,4,5-Trimethoxybenzamido)Ethylthio]Benzenesulphonyl} Guanadines, ” Acta Poloniae Pharmaceutica-Drug Research 50(4-5):345-352 (1993).
Carter et al., Chemotherapy of Cancer, 2nded., John Wiley & Sons, N.Y., N.Y. 1987, pp. 362-365.
Hines, J.W. and Stammer, C.H., “3-Hydroxyisoxazole-5-hydroxamic Acid,” J. Med. Chem. 20(7):965-967 (1977).
LaVoie, R., “Design and Synthesis of a Novel Class of Histone Deacetylase Inhibitors,” Bioorg. Med. Chem. Ltrs. 11:2847-2850 (2001).
Uesato, S., “Novel Histone Deacetylase Inhibitors: N-Hydroxycarboxamides Possessing a Terminal Bicyclic Aryl Group,” Bioorg. Med. Chem. Ltrs. 12:1347-1349 (2002).
Watanabe, S et al., “Synthesis of 4-[1-(substituted phenyl)-2-oxo-pyrrolidin4-yl]methyloxybenzoic acids and related compounds, and their inhibitory capacities toward fatty-acid and sterol biosynthesis,” Eur. J. Med. Chem. 29:675-686 (1994).

Affiliated with

Also associated with

Rating

Hydroxamates as therapeutic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hydroxamates as therapeutic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydroxamates as therapeutic agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3985001